Новости портфельных компаний

  • 20 Декабря 2012

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. Completes $20.6 Million Equity Financing

    Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. The investment was led by RusnanoMedInvest (“RMI” a subsidiary of RUSNANO) made in connection with a joint investment collaboration with Domain Associates.

  • 24 Июля 2012

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics Completes $49 Million Fund Raising

    CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.

  • 06 Октября 2011

    Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

    Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.

  • 29 Апреля 2011

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals Issued Patent for Ganaxolone

    Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.  

  • 18 Апреля 2011

    CoDa Therapeutics Closes $19 Million Series B Financing Round

    San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.

  • 17 Апреля 2011

    Marinus Pharmaceuticals Announces U.S.  Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

    Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

    Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.

Все Портфель

Медиа центр

  • НоваМедика начала строительство фармацевтического завода в Калужской области

    НоваМедика начала строительство фармацевтического завода в Калужской области

    Российская фармацевтическая компания «НоваМедика», портфельная компания Роснано, объявляет о старте строительства завода по производству стерильных инъекционных препаратов в рамках своей долгосрочной стратегии по локализации в России инновационных лекарственных препаратов и технологий их разработки и производства. Завод будет построен на территории индустриального парка «Ворсино» в Калужской области.

Перейти в медиа-центр